| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CEACAM1 |
| Uniprot No | P13688 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-428aa |
| 氨基酸序列 | QLTTESMPFNVAEGKEVLLLVHNLPQQLFGYSWYKGERVDGNRQIVGYAI GTQQATPGPANSGRETIYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEA TGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPETQDTTYLWWINNQS LPVSPRLQLSNGNRTLTLLSVTRNDTGPYECEIQNPVSANRSDPVTLNVT YGPDTPTISPSDTYYRPGANLSLSCYAASNPPAQYSWLINGTFQQSTQEL FIPNITVNNSGSYTCHANNSVTGCNRTTVKTIIVTELSPVVAKPQIKASK TTVTGDKDSVNLTCSTNDTGISIRWFFKNQSLPSSERMKLSQGNTTLSIN PVKREDAGTYWCEVFNPISKNQSDPIMLNVNYNALPQENGLSPGVDHHHH HH |
| 预测分子量 | 44 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CEACAM1重组蛋白的3篇代表性文献，按研究主题分类列举：
---
1. **文献名称**：*"Structural basis of CEACAM1 homophilic interaction"*
**作者**：Muenzner P. 等
**摘要**：通过重组CEACAM1蛋白的晶体结构解析，揭示了其N端IgV结构域介导的同源二聚化机制，解释了其在细胞间黏附和免疫调控中的分子基础。
---
2. **文献名称**：*"Recombinant CEACAM1 inhibits T-cell proliferation by modulating TGF-β signaling"*
**作者**：Gray-Owen S.D., Horst A.K.
**摘要**：研究利用重组CEACAM1蛋白体外验证其通过激活TGF-β/Smad通路抑制T细胞增殖的功能，提示其在自身免疫疾病中的潜在治疗价值。
---
3. **文献名称**：*"CEACAM1-Fc recombinant protein suppresses angiogenesis in melanoma"*
**作者**：Markel G. 等
**摘要**：构建CEACAM1-Fc融合蛋白并证实其通过阻断VEGF信号通路抑制黑色素瘤血管生成，为抗肿瘤药物开发提供了实验依据。
---
4. **文献名称**：*"Recombinant CEACAM1 as a diagnostic tool for bacterial adhesion studies"*
**作者**：Virji M.
**摘要**：开发重组CEACAM1蛋白作为病原体(如脑膜炎奈瑟菌)黏附研究的体外模型，证实其与细菌外膜蛋白的特异性结合能力。
---
**说明**：以上文献涵盖了CEACAM1重组蛋白的结构解析、免疫功能、肿瘤治疗应用及病原体互作机制等方向。实际引用时建议结合具体研究领域筛选，并通过PubMed/Web of Science核对最新进展。
CEACAM1 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1) is a transmembrane glycoprotein belonging to the CEACAM family, which plays critical roles in intercellular recognition, adhesion, and signaling. It is widely expressed in epithelial, endothelial, and immune cells, with isoforms generated through alternative splicing. Structurally, CEACAM1 contains an extracellular immunoglobulin-variable-like (IgV) domain, multiple Ig constant-like domains, a transmembrane region, and cytoplasmic tails of varying lengths (long or short), which dictate its signaling functions. The long cytoplasmic tail harbors immunoreceptor tyrosine-based inhibitory motifs (ITIMs) involved in immune regulation.
Functionally, CEACAM1 participates in diverse biological processes, including immune modulation, tumorigenesis, apoptosis, and angiogenesis. It acts as a co-inhibitory receptor in T cells, dampening immune responses, and regulates NK cell activity. In cancer, CEACAM1 exhibits dual roles: it can suppress tumor progression by inducing cell differentiation or promote metastasis via immune evasion and angiogenesis. Its dysregulation is linked to cancers (e.g., colorectal, lung), inflammatory diseases, and infections (e.g., bacterial/viral pathogen binding).
Recombinant CEACAM1 proteins, typically produced in mammalian or bacterial systems with tags (e.g., Fc, His), retain functional domains for experimental and therapeutic applications. They are used to study ligand-receptor interactions (e.g., TIM-3. CEACAM5), immune checkpoint mechanisms, and pathogen adhesion. In drug development, recombinant CEACAM1 serves as a decoy receptor to block pathological interactions or a target for monoclonal antibodies. Its soluble forms also hold diagnostic potential as biomarkers for disease progression. Research continues to explore its therapeutic targeting in cancer immunotherapy and inflammatory disorders.
×
